As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications

As I See It: Access to data

As I See It: Access to data

We need for pharmaceutical companies to come forward and make the pledge to stop hiding data

As I See It: FDA and the First Amendment

As I See It: FDA and the First Amendment

FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals

As I See It: Small is the new Big

As I See It: Small is the new Big

It's fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes

As I See It: Quality programs

As I See It: Quality programs

Keeping up with quality programs often feels like a safari in a jungle of government paperwork

As I See It: FDA reorganization

As I See It: FDA reorganization

Could PAG change the FDA inspection paradigm from honest, objective assessments to faster, easier ones?

As I See It: Transparency and clinical trial data

As I See It: Transparency and clinical trial data

By opposing making clinical trial data public, Pharma is once again swimming against the current

As I See It: The Sunshine Act's CME exclusion

As I See It: The Sunshine Act's CME exclusion

CMS recognized that the rules in place for CME provide for separation from supporter influence

Email Newsletters

MM&M inVISION